Aug 9, 2010 | Laboratory News, Laboratory Pathology
Testing ceases following July 19 inspection by officials from CMS and CAP
Last Friday, The Washington Post broke the news that Georgetown University Hospital (GUH) had closed the pathology laboratory that performed certain breast cancer tests. The action—described as an “unprecedented” suspension by GUH Chief Medical Officer Stephen Evans, M.D.—was taken in response to an investigation of the pathology laboratory by federal officials.
The closure of the laboratory followed an inspection on July 19, 2010 by officials from the Centers for Medicare and Medicaid Services (CMS) and inspectors from the College of American Pathologists (CAP). Hospital officials say the molecular testing laboratory in question will be closed as long as four to eight weeks. During this time, specimens are being referred to outside laboratory testing sources.
(more…)
Feb 24, 2010 | Laboratory News, Laboratory Pathology, Uncategorized
In recent years, Newfoundland pathology lab’s errors involving breast cancer testing made headlines
Once again, Newfoundland finds itself in the headlines about healthcare. This time it is not about breast cancer testing problems in its pathology laboratories. Instead, media reports are trumpeting the disclosure that Newfoundland Premier Danny Williams had quietly left the country earlier this month to undergo major heart surgery in the United States.
Danny Williams’ decision caused negative reactions among the press and commentators in the United States and Canada. After all, why would a senior elected official from Newfoundland decide to leave Canada, which has national health insurance, and seek care in the U.S., where the Congress is debating the merits of a national health insurance plan? It was disclosed that Williams underwent a major heart procedure on Thursday, February 4, at an undisclosed hospital in Florida.
(more…)
Jun 1, 2009 | Laboratory Management and Operations, Laboratory News, Laboratory Pathology
Health minister characterizes reports of 20% to 30% error rates as highly exaggerated
Questions about a possible high rate of errors in breast cancer testing done in the Canadian province of Quebec surfaced last week. Government health officials were forced to publicly acknowledge that they had received a report in April of a limited study that indicated an error rate of between 15% and 20% in hormone receptor testing, and an error rate as high as 30% in HER2/neu testing.
Following the first news reports of this situation last Thursday, Quebec health officials scrambled to respond to public concerns. In response to calls for the Health Ministry to release the full report to the public, Quebec’s Health Minister, Yves Bolduc, convened an extraordinary Sunday meeting that took place yesterday. He met with pathologists and oncologists from the province to review the details of the report on errors in breast cancer testing and determine a course of action.
(more…)
